Gritstone Bio Gross Profit 2017-2024 | GRTSQ
Gritstone Bio gross profit from 2017 to 2024. Gross profit can be defined as the profit a company makes after deducting the variable costs directly associated with making and selling its products or providing its services.
Gritstone Bio Annual Gross Profit
(Millions of US $) |
| 2023 |
$16 |
| 2022 |
$20 |
| 2021 |
$48 |
| 2020 |
$4 |
| 2019 |
$4 |
| 2018 |
$1 |
| 2017 |
$ |
| 2016 |
$ |
Gritstone Bio Quarterly Gross Profit
(Millions of US $) |
| 2024-06-30 |
$1 |
| 2024-03-31 |
$2 |
| 2023-12-31 |
$10 |
| 2023-09-30 |
$2 |
| 2023-06-30 |
$2 |
| 2023-03-31 |
$2 |
| 2022-12-31 |
$4 |
| 2022-09-30 |
$3 |
| 2022-06-30 |
$5 |
| 2022-03-31 |
$7 |
| 2021-12-31 |
$3 |
| 2021-09-30 |
$3 |
| 2021-06-30 |
$3 |
| 2021-03-31 |
$40 |
| 2020-12-31 |
$1 |
| 2020-09-30 |
$1 |
| 2020-06-30 |
$0 |
| 2020-03-31 |
$1 |
| 2019-12-31 |
$1 |
| 2019-09-30 |
$1 |
| 2019-06-30 |
$1 |
| 2019-03-31 |
$1 |
| 2018-12-31 |
$1 |
| 2018-09-30 |
$0 |
| 2018-06-30 |
|
| 2018-03-31 |
|
| 2017-12-31 |
|
| 2017-09-30 |
|
| 2016-12-31 |
|
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
MED-BIOMED/GENE |
$0.000B |
$0.016B |
|
Gritstone Oncology is developing tumor-specific cancer immunotherapies to fight multiple cancer types. The company has built its tumor-specific immunotherapy approach on two key pillars - first, a proprietary machine learning-based platform, Gritstone EDGE(TM), which provides a powerful ability to predict from a routine tumor biopsy the tumor-specific neoantigens, or TSNA, that are presented on a patient?s tumor cells; and second, the ability to develop and manufacture potent immunotherapies utilizing patients? TSNA to drive the patient?s immune system to attack and destroy tumors.
|
